Pebbles Shanley, MD
Family Medicine · Anchorage, AKNPI 1962842260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$632
- AstraZeneca$545
- Astellas Pharma US Inc$460
- Novo Nordisk$389
- GSK$217
- Lilly USA, LLC$209
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,47695%
- Education$1745%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $632 |
| AstraZeneca(2 entities) | 29 | $545 |
| Astellas Pharma US Inc | 13 | $460 |
| Novo Nordisk | 26 | $389 |
| GSK | 13 | $217 |
| Lilly USA, LLC | 11 | $209 |
| Sumitomo Pharma America, Inc. | 5 | $105 |
| Pfizer | 5 | $90 |
| Novartis | 4 | $89 |
| Exact Sciences | 4 | $87 |
| Merck | 5 | $70 |
| Ascendis Pharma Endocrinology Inc | 2 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Amgen(2 entities) | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Sage Therapeutics, LLC | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Kyowa Kirin, Inc. | 2 | $39 |
| Abbott | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Myovant Sciences Inc. | 1 | $26 |
| Neuronetics, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| GRT US Holding, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
How this compares
$3,650 in reported general payments places this provider in the 90th percentile of 334 family medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $67,199 |
| EliquisApixaban | 37 | $33,141 |
| MounjaroTirzepatide | 17 | $27,784 |
| TrulicityDulaglutide | 13 | $24,700 |
| JanuviaSitagliptin Phosphate | 16 | $19,218 |
| JardianceEmpagliflozin | 18 | $18,052 |
| MyrbetriqMirabegron | 14 | $17,073 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,101 |
| XareltoRivaroxaban | 13 | $10,123 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $8,454 |
| GemtesaVibegron | 12 | $8,439 |
| Metformin Er OsmoticMetformin Hcl | 19 | $3,586 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,719 |
| Rosuvastatin Calcium | 101 | $2,186 |
| SynthroidLevothyroxine Sodium | 16 | $2,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $389 | $67,19961 claims |
| Lilly USA, LLCMounjaro, Trulicity | $209 | $52,48430 claims |
| PfizerEliquis | $90 | $33,14137 claims |
| MerckJanuvia | $70 | $19,21816 claims |
| Astellas Pharma US IncMyrbetriq | $460 | $17,07314 claims |
| GSKTrelegy Ellipta | $217 | $15,10122 claims |
| Johnson & JohnsonXarelto | $13 | $10,12313 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $105 | $8,43912 claims |
| AbbVieSynthroid | $632 | $2,00516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 family medicine providers in Alaska.
Other family medicine in Anchorage
- Mary FolandAnchorage$15K
- Ilona FarrAnchorage$14K
- Eric MiknichAnchorage$13K
- Allison KelliherAnchorage$6K
- Bruce KiesslingAnchorage$5K
- Kathryn RyanAnchorage$5K
- Bruck CliftAnchorage$5K
- Ulyana StiassnyAnchorage$4K
- Kenneth MollAnchorage$3K
- Jane SimonoAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.